Clinical trial data for the vaccines show they were safe but did not generate enough of an immune response to effectively protect recipients against COVID-19.
While Merck is shelving its two vaccine candidates, the drugmaker said it will keep producing two drugs that treat COVID-19.
The drugmaker is continuing to produce MK-7110, which aims to modulate the respiratory system’s inflammatory response to COVID-19. Merck signed a $356 million agreement with the U.S. government Dec. 23 to supply up to 100,000 doses of MK-7110, and it is also continuing to produce MK-4482, an antiviral drug.
More articles on pharmacy:
FDA approves first monthly injectable to treat HIV
Amazon, Seattle health system create vaccination pop-up site
Premier, Pfizer partner to supply 5 critical drugs
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
